Year |
Citation |
Score |
2023 |
Subash S, Singh DK, Ahire DS, Khojasteh SC, Murray BP, Zientek MA, Jones RS, Kulkarni P, Smith BJ, Heyward S, Cronin CN, Prasad B. . Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 37429730 DOI: 10.1124/dmd.123.001379 |
0.325 |
|
2023 |
Zhang C, Su D, Choo EF, Liu L, Bobba S, Jorski J, Ho Q, Wang J, Kenny J, Khojasteh SC, Zhang D. . Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 37349116 DOI: 10.1124/dmd.122.001071 |
0.311 |
|
2023 |
Wang S, Ma S, Chen E, Wang J, Le H, Hanlon SP, Binder M, Lee W, Khojasteh SC, Salphati L. Mass Balance of the IDO Inhibitor in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-a]isoindole and Species Differences in Glucuronidation. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 37059472 DOI: 10.1124/dmd.123.001289 |
0.349 |
|
2022 |
Guo Y, Ji S, Wang W, Wong S, Yen CW, Hu C, Leung DH, Plise E, Zhang S, Zhang C, Anene UA, Zhang D, Cunningham CN, Khojasteh SC, Su D. An Integrated Strategy for Assessing the Metabolic Stability and Biotransformation of Macrocyclic Peptides in Drug Discovery toward Oral Delivery. Analytical Chemistry. PMID 35041378 DOI: 10.1021/acs.analchem.1c04008 |
0.354 |
|
2021 |
Yue Q, Khojasteh SC, Cho S, Ma S, Mulder T, Chen J, Pang J, Ding X, Deese A, Pellet J, Siebers N, Joas L, Salphati L, Ware J. Absorption, metabolism and excretion of pictilisib, a potent Pan-Class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-45. PMID 33938357 DOI: 10.1080/00498254.2021.1923859 |
0.344 |
|
2021 |
Yip V, Lee MV, Saad OM, Ma S, Khojasteh SC, Shen BQ. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY) Antibody-Drug Conjugate in Sprague Dawley Rats. Journal of Clinical Medicine. 10. PMID 33806916 DOI: 10.3390/jcm10061323 |
0.318 |
|
2020 |
Basit A, Neradugomma NK, Wolford C, Fan PW, Murray B, Takahashi RH, Khojasteh SC, Smith BJ, Heyward S, Totah RA, Kelly EJ, Prasad B. CHARACTERIZATION OF DIFFERENTIAL TISSUE ABUNDANCE OF MAJOR NON-CYP ENZYMES IN HUMAN. Molecular Pharmaceutics. PMID 32955894 DOI: 10.1021/Acs.Molpharmaceut.0C00559 |
0.4 |
|
2020 |
Cai H, Yip V, Lee MV, Wong S, Saad O, Ma S, Ljumanovic N, Khojasteh SC, Kamath AV, Shen BQ. . Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 32839277 DOI: 10.1124/Dmd.120.000092 |
0.38 |
|
2020 |
Staben LR, Chen J, Cruz-Chuh JD, Del Rosario G, Go MA, Guo J, Khojasteh SC, Kozak KR, Li G, Ng C, Lewis Phillips G, Pillow TH, Rowntree RK, Wai J, Wei B, et al. Systematic Variation of Pyrrolobenzodiazepine (PBD)-dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates. Journal of Medicinal Chemistry. PMID 32787101 DOI: 10.1021/Acs.Jmedchem.0C00691 |
0.35 |
|
2020 |
Wang W, Teresa M, Cai J, Zhang C, Wong S, Yan Z, Khojasteh SC, Zhang D. Comparative assessment for rat strain differences in metabolic profiles of 14 drugs in Wistar Han and Sprague Dawley hepatocytes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-9. PMID 32713280 DOI: 10.1080/00498254.2020.1795949 |
0.393 |
|
2020 |
Khojasteh SC, Driscoll JP, Jackson KD, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Novel advances in biotransformation and bioactivation research-2019 year in review. Drug Metabolism Reviews. 1-33. PMID 32645275 DOI: 10.1080/03602532.2020.1772281 |
0.36 |
|
2020 |
Mulder T, Bobba S, Johnson K, Grandner JM, Wang W, Zhang C, Cai J, Choo EF, Khojasteh SC, Zhang D. . Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 32616543 DOI: 10.1124/Dmd.120.000096 |
0.37 |
|
2020 |
Zhang C, Crawford JJ, Landry ML, Chen H, Kenny JR, Khojasteh SC, Lee W, Ma S, Young WB. Strategies to Mitigate the Bioactivation of Aryl Amines. Chemical Research in Toxicology. PMID 32508087 DOI: 10.1021/Acs.Chemrestox.0C00138 |
0.409 |
|
2019 |
Zhang D, Dragovich PS, Yu SF, Ma Y, Pillow TH, Sadowsky JD, Su D, Wang W, Polson A, Khojasteh SC, Hop CE. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31358513 DOI: 10.1124/Dmd.119.087023 |
0.334 |
|
2019 |
Zhang D, Hop CE, Patilea-Vrana G, Gampa G, Seneviratne HK, Unadkat JD, Kenny JR, Nagapudi K, Di L, Zhou L, Zak M, Wright MR, Bumpus NN, Zang R, Liu X, ... ... Khojasteh SC, et al. Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31266753 DOI: 10.1124/Dmd.119.086744 |
0.362 |
|
2019 |
Khojasteh SC, Bumpus NN, Driscoll JP, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Biotransformation and Bioactivation Reactions - 2018 Literature Highlights. Drug Metabolism Reviews. 1-72. PMID 31170851 DOI: 10.1080/03602532.2019.1615937 |
0.368 |
|
2019 |
Zhang D, Fourie-O'Donohue A, Dragovich PS, Pillow TH, Sadowsky JD, Kozak KR, Cass RT, Liu L, Deng Y, Liu Y, Hop CE, Khojasteh SC. Catalytic cleavage of disulfide bonds in small molecules and linkers of antibody- drug conjugates. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31085544 DOI: 10.1124/Dmd.118.086132 |
0.373 |
|
2019 |
Ma Y, Cruz-Chuh JD, Khojasteh SC, Dragovich PS, Pillow TH, Zhang D. Carfilzomib is not an appropriate payload of antibody-drug conjugates as rapid inactivation by lysosomal enzymes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 31072822 DOI: 10.1124/Dmd.119.086595 |
0.393 |
|
2018 |
Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, Nedderman ANR, Prakash C, Runge F, Scheible H, Spracklin DK, et al. A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development Under the "Metabolites in Safety Testing" Regulatory Guidances. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29487142 DOI: 10.1124/Dmd.117.079848 |
0.428 |
|
2018 |
Zhang D, Yu SF, Khojasteh SC, Ma Y, Pillow TH, Sadowsky JD, Su D, Kozak KR, Xu K, Polson AG, Dragovich P, Hop CE. Intratumoral Payload Concentration Correlates with the Activity of Antibody- Drug Conjugates. Molecular Cancer Therapeutics. PMID 29348271 DOI: 10.1158/1535-7163.Mct-17-0697 |
0.356 |
|
2017 |
Takahashi RH, Wang X, Segraves NL, Wang J, Chang JH, Khojasteh SC, Ma S. CYP1A1-Mediated Intramolecular Rearrangement of Aminoazepane in GDC-0339. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28790146 DOI: 10.1124/Dmd.117.076786 |
0.383 |
|
2017 |
Ma Y, Fu Y, Khojasteh SC, Dalvie D, Zhang D. Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). Journal of Medicinal Chemistry. PMID 28653847 DOI: 10.1021/Acs.Jmedchem.7B00510 |
0.408 |
|
2017 |
Takahashi RH, Halladay JS, Siu M, Chen Y, Hop CE, Khojasteh SC, Ma S. Novel Mechanism of Decyanation of GDC-0425 by Cytochrome P450. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28188299 DOI: 10.1124/Dmd.116.074336 |
0.476 |
|
2017 |
Zhang C, Zhang D, Choo EF, DeMent K, Savage S, Khojasteh SC. Identification and profiling of GDC-0810 metabolites from admistration of a single oral dose of 14C GDC-0810 to intact and bile duct cannulated (BDC) rats Drug Metabolism and Pharmacokinetics. 32: S76. DOI: 10.1016/J.Dmpk.2016.10.302 |
0.364 |
|
2017 |
Ma S, Salphati L, Srikumar S, Takahashi R, Ding X, Pang J, Wang B, Remarchuk T, Hsu J, Hop C(, Ware JA, Khojasteh SC. Absorption, metabolism, and excretion of taselisib (GDC-0032), a PI3K inhibitor, in rats, dogs, and humans Drug Metabolism and Pharmacokinetics. 32: S74-S75. DOI: 10.1016/J.Dmpk.2016.10.296 |
0.382 |
|
2016 |
Zhang D, Pillow TH, Ma Y, Cruz-Chuh JD, Kozak KR, Sadowsky JD, Lewis Phillips GD, Guo J, Darwish M, Fan P, Chen J, He C, Wang T, Yao H, Xu Z, ... ... Khojasteh SC, et al. Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates. Acs Medicinal Chemistry Letters. 7: 988-993. PMID 27882196 DOI: 10.1021/Acsmedchemlett.6B00233 |
0.325 |
|
2016 |
Zhang D, Yu SF, Ma Y, Xu K, Dragovich PS, Pillow TH, Liu L, Del Rosario G, He J, Pei Z, Sadowsky JD, Erickson HK, Hop CE, Khojasteh SC. The chemical structure and concentration of intratumor catabolites determine the efficacy of antibody drug conjugates. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27417182 DOI: 10.1124/Dmd.116.070631 |
0.375 |
|
2016 |
Takahashi RH, Ma S, Yue Q, Kim-Kang H, Yi Y, Ly J, Boggs JW, Fettes A, McClory A, Deng Y, Hop CE, Khojasteh SC, Choo EF. Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-16. PMID 27055783 DOI: 10.3109/00498254.2016.1157645 |
0.446 |
|
2015 |
Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng A, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser M, Musib L. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26451002 DOI: 10.1124/Dmd.115.066282 |
0.427 |
|
2015 |
Takahashi RH, Ma S, Robinson SJ, Yue Q, Choo EF, Khojasteh SC. Elucidating the Mechanisms of Formation for Two Unusual P450-Mediated Fused Ring Metabolites of GDC-0623, a MEK Inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26438627 DOI: 10.1124/Dmd.115.067181 |
0.371 |
|
2015 |
Saad OM, Shen BQ, Xu K, Khojasteh SC, Girish S, Kaur S. Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. Bioanalysis. 7: 1583-604. PMID 26226309 DOI: 10.4155/Bio.15.87 |
0.372 |
|
2015 |
Shen BQ, Bumbaca D, Yue Q, Saad O, Tibbitts J, Khojasteh SC, Girish S. Non-clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats. Drug Metabolism Letters. PMID 26031461 DOI: 10.2174/1872312809666150602151922 |
0.431 |
|
2015 |
Aliagas I, Gobbi A, Heffron T, Lee ML, Ortwine DF, Zak M, Khojasteh SC. A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery. Journal of Computer-Aided Molecular Design. 29: 327-38. PMID 25708388 DOI: 10.1007/S10822-015-9838-3 |
0.364 |
|
2015 |
Gordon P, Khojasteh SC. A decades-long investigation of acute metabolism-based hepatotoxicity by herbal constituents: a case study of pennyroyal oil. Drug Metabolism Reviews. 47: 12-20. PMID 25512112 DOI: 10.3109/03602532.2014.990032 |
0.362 |
|
2015 |
Takahashi R, Ma S, Yue Q, Kim-Kang H, Yi Y, Lyssikatos JP, Regal K, Hunt KW, Kallan NC, Siu M, Hop CE, Liu X, Khojasteh SC. Dose-dependent exposure and metabolism of GNE-892, a β-secretase inhibitor, in monkeys: contributions by P450, AO, and P-gp. European Journal of Drug Metabolism and Pharmacokinetics. 40: 171-85. PMID 24696325 DOI: 10.1007/S13318-014-0198-5 |
0.415 |
|
2014 |
Fan PW, Song Y, Berezhkovskiy LM, Cheong J, Plise EG, Khojasteh SC. Practical permeability-based hepatic clearance classification system (HepCCS) in drug discovery. Future Medicinal Chemistry. 6: 1995-2012. PMID 25531965 DOI: 10.4155/Fmc.14.141 |
0.375 |
|
2014 |
Tay S, Le H, Ford KA, Nelson SD, Khojasteh SC, Rademacher PM. Mechanistic studies of the cationic binding pocket of CYP2C9 in vitro and in silico: metabolism of nonionizable analogs of tienilic acid. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1955-63. PMID 25187484 DOI: 10.1124/Dmd.114.059022 |
0.554 |
|
2014 |
Takahashi R, Ma S, Deese A, Yue Q, Kim-Kang H, Yi Y, Siu M, Hunt KW, Kallan NC, Hop CE, Liu X, Khojasteh SC. Elucidating the mechanism of cytochrome P450-mediated pyrimidine ring conversion to pyrazole metabolites with the BACE1 inhibitor GNE-892 in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 890-8. PMID 24595682 DOI: 10.1124/Dmd.114.057141 |
0.45 |
|
2014 |
Sodhi JK, Ford KA, Mukadam S, Wong S, Hop CE, Khojasteh SC, Halladay JS. 1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 813-7. PMID 24550229 DOI: 10.1124/Dmd.113.055913 |
0.341 |
|
2014 |
Khojasteh SC, Yue Q, Ma S, Castanedo G, Chen JZ, Lyssikatos J, Mulder T, Takahashi R, Ly J, Messick K, Jia W, Liu L, Hop CE, Wong H. Investigations into the mechanisms of pyridine ring cleavage in vismodegib. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 343-51. PMID 24389420 DOI: 10.1124/Dmd.113.055715 |
0.34 |
|
2014 |
Zhang C, Ma S, Delarosa EM, Tay S, Sodhi J, Musinipally V, Chang P, Pai R, Halladay JS, Misner D, Kenny JR, Hop CECA, Khojasteh SC. For a series of methylindole analogs, reactive metabolite formation is a poor predictor of intrinsic cytotoxicity in human hepatocytes Toxicology Research. 3: 184-190. DOI: 10.1039/C3Tx50062D |
0.373 |
|
2013 |
Yue Q, Mulder T, Rudewicz PJ, Solon E, Budha N, Ware JA, Lyssikatos J, Hop CE, Wong H, Khojasteh SC. Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3-thiadiazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 508-17. PMID 23223496 DOI: 10.1124/Dmd.112.047019 |
0.407 |
|
2013 |
Le H, Ford KA, Khojasteh SC, Fan PW. Elucidation of the mechanism of ribose conjugation in a pyrazole-containing compound in rodent liver. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 43: 236-45. PMID 22931212 DOI: 10.3109/00498254.2012.715211 |
0.316 |
|
2012 |
Khojasteh SC, Hartley DP, Ford KA, Uppal H, Oishi S, Nelson SD. Characterization of rat liver proteins adducted by reactive metabolites of menthofuran. Chemical Research in Toxicology. 25: 2301-9. PMID 23106769 DOI: 10.1021/Tx300144D |
0.514 |
|
2012 |
Halladay JS, Wong S, Khojasteh SC, Grepper S. An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes. Journal of Pharmacological and Toxicological Methods. 66: 270-5. PMID 22809809 DOI: 10.1016/J.Vascn.2012.07.004 |
0.39 |
|
2012 |
Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, LoRusso PM, Girish S. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Current Drug Metabolism. 13: 901-10. PMID 22475269 DOI: 10.2174/138920012802138598 |
0.352 |
|
2012 |
Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, Khojasteh SC. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharmaceutical Research. 29: 1960-76. PMID 22415140 DOI: 10.1007/S11095-012-0724-6 |
0.365 |
|
2012 |
Mukadam S, Tay S, Tran D, Wang L, Delarosa EM, Khojasteh SC, Halladay JS, Kenny JR. Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug Metabolism Letters. 6: 43-53. PMID 22372554 DOI: 10.2174/187231212800229309 |
0.364 |
|
2011 |
Zhang C, Kenny JR, Le H, Deese A, Ford KA, Lightning LK, Fan PW, Driscoll JP, Halladay JS, Hop CE, Khojasteh SC. Novel mechanism for dehalogenation and glutathione conjugation of dihalogenated anilines in human liver microsomes: evidence for ipso glutathione addition. Chemical Research in Toxicology. 24: 1668-77. PMID 21905702 DOI: 10.1021/Tx2002228 |
0.368 |
|
2011 |
Halladay JS, Delarosa EM, Tran D, Wang L, Wong S, Khojasteh SC. High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis. Drug Metabolism Letters. 5: 220-30. PMID 21867481 DOI: 10.2174/187231211796905017 |
0.309 |
|
2011 |
Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, Kuebler P, Davis JC, Liao XC, Lubach JW, Deese A, ... ... Khojasteh SC, et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1840-9. PMID 21742900 DOI: 10.1124/Dmd.111.040840 |
0.367 |
|
2011 |
Yue Q, Chen YH, Mulder T, Deese A, Takahashi R, Rudewicz PJ, Reynolds M, Solon E, Hop CE, Wong H, Khojasteh SC. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 952-65. PMID 21363998 DOI: 10.1124/Dmd.110.037374 |
0.42 |
|
2011 |
Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. European Journal of Drug Metabolism and Pharmacokinetics. 36: 1-16. PMID 21336516 DOI: 10.1007/s13318-011-0024-2 |
0.348 |
|
2010 |
Khojasteh SC, Oishi S, Nelson SD. Metabolism and toxicity of menthofuran in rat liver slices and in rats. Chemical Research in Toxicology. 23: 1824-32. PMID 20945912 DOI: 10.1021/Tx100268G |
0.562 |
|
2010 |
Wong H, Theil FP, Cui Y, Marsters JC, Khojasteh SC, Vernillet L, La H, Song X, Wang H, Morinello EJ, Deng Y, Hop CE. Interplay of dissolution, solubility, and nonsink permeation determines the oral absorption of the Hedgehog pathway inhibitor GDC-0449 in dogs: an investigation using preclinical studies and physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 1029-38. PMID 20406853 DOI: 10.1124/Dmd.110.032680 |
0.327 |
|
2009 |
Wong H, Chen JZ, Chou B, Halladay JS, Kenny JR, La H, Marsters JC, Plise E, Rudewicz PJ, Robarge K, Shin Y, Wong S, Zhang C, Khojasteh SC. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4- (methylsulfonyl)benzamide), an orally bioavailable systemic hedgehog signalling pathway inhibitor Xenobiotica. 39: 850-861. PMID 19845436 DOI: 10.3109/00498250903180289 |
0.313 |
|
2009 |
Berezhkovskiy LM, Khojasteh SC, Halladay JS, Hop CE. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay. Journal of Pharmaceutical Sciences. 98: 1922-7. PMID 18837013 DOI: 10.1002/Jps.21582 |
0.323 |
|
2008 |
Khojasteh SC, Leipold DD, Lai F, La H, Baumgardner MJ, Desino KE, Gudmundsson OS, Bloedow DC, Bodary SC, Reynolds ME, Gadek TR, Kenkare-Mitra S. Preclinical absorption, distribution, metabolism and excretion (ADME) characterization of ICAM1988, an LFA-1/ICAM antagonist, and its prodrug Xenobiotica. 38: 340-352. PMID 18274961 DOI: 10.1080/00498250701813248 |
0.321 |
|
Show low-probability matches. |